Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,156.40.
2 Nov: open ₹1,160.00, high ₹1,186.90, low ₹1,150.60
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,096 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.75
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 45,47355.9% delivered
Eris Lifesciences share news and announcements
795 announcements, routine notices left out, newest first. Page 11 of 16.
Jun 2020
26 Jun · Results
26 Jun · Board meeting
23 Jun · Board meeting
16 Jun · Legal
The exchange asked on 15 Jun 2020
6 Jun · Analysts
4 Jun · Analysts
3 Jun · Updates
2 Jun · Board meeting
1 Jun · Analysts
May 2020
30 May · Board meeting
Apr 2020
17 Apr · Legal
The exchange asked on 16 Apr 2020
10 Apr · Analysts
9 Apr · Analysts
8 Apr · Dividend
8 Apr · Analysts
7 Apr · Analysts
Mar 2020
18 Mar · Analysts
12 Mar · Analysts
6 Mar · Analysts
5 Mar · Corporate action
5 Mar · Board meeting
2 Mar · Analysts
Feb 2020
26 Feb · Analysts
18 Feb · Analysts
14 Feb · Results
14 Feb · Board meeting
10 Feb · Analysts
7 Feb · Board meeting
7 Feb · Analysts
Jan 2020
24 Jan · Analysts
23 Jan · Post Buyback Public Announcement
13 Jan · Analysts
Dec 2019
27 Dec · Analysts
26 Dec · Analysts
19 Dec · Analysts
16 Dec · Analysts
13 Dec · Updates
13 Dec · Analysts
10 Dec · Analysts
6 Dec · Legal
Significant increase in volume has been observed in Eris Lifesciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.